Trials / Terminated
TerminatedNCT00501241
Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation
A Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 214 (estimated)
- Sponsor
- Procter and Gamble · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ATI-7505 is effective in the treatment of chronic idiopathic constipation.
Detailed description
This study is designed to evaluate the safety and efficacy of ATI 7505 in generally healthy, adult patients who have had symptoms of chronic idiopathic constipation for at least 6 months as defined in the ROME III criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATI-7505 | Tablet,placebo, BID |
| DRUG | ATI-7505 | ATI-7505 20 mg BID for 4 weeks |
| DRUG | ATI-7505 | tablet, 40 mg, BID, $ weeks |
| DRUG | ATI-7505 | 80 mg ATI-7505, BID for 4 weeks |
| DRUG | ATI-7505 | 120 mg ATI-7505, BID, for 4 weeks |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2007-07-16
- Last updated
- 2009-06-17
Locations
23 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00501241. Inclusion in this directory is not an endorsement.